ACTRN12617000375358RecruitingPhase 2
Safety and immunogenicity of Q fever vaccine in children aged 10 to 15 years.
The Children's Hospital at Westmead0 sites20 target enrollmentStarted: March 13, 2017Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 10 Years to 14 Years (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Withdrawn
Phase 2
Safety and Immunogenicity of Q Fever VaccineQ FeverNCT02092142U.S. Army Medical Research and Development Command
Recruiting
Phase 3
Evaluation of the immunogenicity and safety of quadrivalent seasonal flu vaccine and comparison with influenza vaccine named VaxigripIRCT20200318046812N4ivad Pharmed Salamat Company1,369
Active, not recruiting
Phase 1
Immunogenicity and Safety of Quadrivalent Influenza Vaccine (VaxigripTetra™) inPregnant WomeEUCTR2016-004763-40-FISanofi Pasteur729
Active, not recruiting
Not Applicable
Study of Yellow Fever Vaccine Administered With Sanofi Pasteur's Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and PeruPrevention of symptomatic dengue diseaseEUCTR2014-001714-26-Outside-EU/EEASanofi Pasteur SA792
Completed
Not Applicable
Q-fever post-vaccination studyCoxiella burnetii infectionQ-fever10004018NL-OMON35763RIVM400